Sign In
Buy CRSP
$52.08
+0.0600 (+0.115%)
At Close: Jun 03, 2026
CRISPR Therapeutics' (CRSP) Pipeline Development Fuels Growth
12:02pm, Tuesday, 06'th Sep 2022
While CRISPR Therapeutics' (CRSP) lead candidate is still a couple of years away from commercialization, it is highly dependent on collaboration revenues to fund its ongoing pipeline.
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
03:26pm, Wednesday, 31'st Aug 2022
The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
08:00am, Wednesday, 31'st Aug 2022
ZUG, Switzerland and CAMBRIDGE, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ser
3 Biotech Stocks You Can Buy and Hold for the Next Decade
02:23pm, Monday, 29'th Aug 2022 The Motley Fool
All three companies are attempting to use unique discoveries to make marketable therapies.
3 Growth Stocks Poised to Skyrocket
10:08am, Saturday, 27'th Aug 2022 The Motley Fool
All of them could have huge catalysts on the way.
7 Cathie Wood Stocks to Buy on the Dip
02:00pm, Monday, 22'nd Aug 2022
Cathie Wood is well-known in the investment world as the face of ARK Invest, the firm she founded in 2014. ARK itself stands for Active Research Knowledge.
5 Cathie Wood Stocks Signaling “The Bear Market Is Over”
01:34pm, Monday, 22'nd Aug 2022
This article is excerpted from Tom Yeung's Profit & Protection newsletter dated Aug. 16, 2022. To make sure you don't miss any of Tom's picks, subscribe to his mailing list here.
Vertex (VRTX) Stock Up 36% This Year So Far: What Lies Ahead?
01:04pm, Monday, 22'nd Aug 2022 Zacks Investment Research
Vertex's (VRTX) CF sales rise 22% in the first half of 2022, primarily driven by higher sales of Trikafta. Programs in five disease areas are now entering or progressing through late-stage clinical de
3 Monster Stocks in the Making to Buy Right Now
10:10am, Saturday, 20'th Aug 2022 The Motley Fool
These stocks have the potential to be huge winners for investors over the long term.
3 Monster Stocks in the Making to Buy Right Now
06:10am, Saturday, 20'th Aug 2022
These stocks have the potential to be huge winners for investors over the long term.
Why This Analyst Sees A 51% Return On This Cathie Wood-Favored Biotech Stock
10:33pm, Wednesday, 17'th Aug 2022 Benzinga
Biotech stocks have the potential for huge gains if a product or drug is deemed effective and safe, but investing in the shares of those companies can be volatile.
Cathie Wood and her flagship ARK Inn
A Comprehensive Guide to Genomic ETFs
12:03pm, Friday, 12'th Aug 2022
Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.
Analysts See Softened Timelines For CRISPR Therapeutics' Sickle Cell Candidate In US
07:26pm, Tuesday, 09'th Aug 2022 Benzinga
Barclays says that CRISPR Therapeutics AG's (NASDAQ: CRSP) Q2 FY22 earnings release was largely incremental, highlighting the progress of multiple clinical programs, including the goal of on-tra
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2022
02:13pm, Tuesday, 09'th Aug 2022 Benzinga
Upgrades
For Nutrien Ltd (NYSE:NTR), Scotiabank upgraded the previous rating of Sector Perform to Sector Outperform. Nutrien earned $5.85 in the second quarter, compared to $2.08 in the year-ago quar
CRISPR Therapeutics (CRSP) Q2 Earnings & Sales Miss Estimates
01:05pm, Tuesday, 09'th Aug 2022 Zacks Investment Research
CRISPR Therapeutics (CRSP) reports a wider-than-expected Q2 loss. Revenues also miss estimates.
